Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 SARS-CoV-2 Vaccine Study to Assess the Safety and Tolerability of GRT-R912, GRT-R914, and GRT-R918 Administered as Prime and/or Boost in Healthy Adult Participants and People Living With HIV

NCT05435027 is registered in ClinicalTrials.gov with Gritstone bio, Inc. as lead sponsor.

NCT NCT05435027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05435027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 SARS-CoV-2 Vaccine Study to Assess the Safety and Tolerability of GRT-R912, GRT-R914, and GRT-R918 Administered as Prime and/or Boost in Healthy Adult Participants and People Living With HIV
Lead sponsor
Gritstone bio, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2022
Completion date
March 6, 2024
Enrollment
342 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2